

## UNITAID

An innovative mechanism for scaling up access to medicines and diagnostics for HIV/AIDS, tuberculosis and malaria

ECOSOC Annual Ministerial Review (Regional Ministerial Meeting on Financing Strategies for Health Care)

Colombo, Sri Lanka, March 2009

Jorge Bermudez, Executive Secretary, UNITAID

UNITAID: What is Innovative?

UN

- An innovative financing mechanism
- Adressing Market Impact for drugs and diagnostics for HIV, TB and malaria
- Working and building solid partnerships



A global challenge for Health...

# Medicines are in the North, patients in the South

Low- and middle-income countries represent:


84% of the world population

Less than 11% of the global health expenditure

More than 93% of the disease burden globally



#### Five founding countries



Official signature of the **five founding countries** when UNITAID was launched, on 19 September 2006, at the United Nations General Assembly, New York


#### **UNITAID** membership

## From 5 founding countries (2006):

Brazil, Chile, France, Norway, UK



Now (2008): supported by 29 countries and the Gates foundation



Together to Hea



#### A flexible 'air tax' approach

Chile - Fixed rate on international flight		US\$ 2		
France - Progressive mechanism				
	Domestic or European flight	International flight		
Economy Class	€ 1	€ 4		
Business & First Class	€ 10	€ 40		
Niger - Progressive mechanism				
	Domestic or West African country flight	International flight		
Economy Class	US\$ 1.20	US\$ 4.70		
Business & First Class	US\$ 6.00	US\$ 24.00		
Norway - CO2 Emission tax				

One dollar makes little difference to a passenger. To a child with malaria, it can mean the difference between life and death

Furthermore... no economic impact on air traffic



#### UNITAID added value

#### UNITAID use of funds allows to:


- Impact markets and reduce prices: more drugs for same budget ex: price reduction on pediatric (- 40%) and 2<sup>nd</sup> line ARVs (-25% to – 50%)
- 2. Have manufactured medicines better adapted to patient needs ex: first fixed dose combinations for pediatric ARVs
- 3. Contribute to address quality issues (incentive for manufacturers to invest) ex: support to WHO program for prequalification of products
- 4. A rapid delivery of medicines to the countries in need (basic model - medicines instead of funds) ex: treatments already provided in a number of countries for ARV, TB and ACT



- Facing a global state of emergency, UNITAID contributes to bring solutions
- In two years, UNITAID has already achieved major results...



UNITAID



All UNITAID funded projects 2008 (90 countries)



Together to Heal




UNITAID funded projects in Africa and Asia

#### Tuberculosis

#### **HIV/AIDS**

#### Malaria



## Over US\$ 900 Million committed funds

HIV / AIDS		
Pediatric ARV	\$121 million	
Second line ARV	\$162 million	
PMTCT	\$75 million	
Total	\$359 million	

Malaria		
ACT	\$209 million	
LLINs	\$109 million	
Total	\$318 million	

UNITAID

Tubercu	Ilosis	
First line TB	\$26 million	Transvers
Pediatric TB	\$11 million	Pre qualifi
MDR-TB	\$71 million	Pre qualifi
Diagnostics	\$26 million	diagnostic
Total	\$136 million	Total

Cross cutting issues				
Transversal	\$52.5 million			
Pre qualification medicines	\$47 million			
Pre qualification diagnostics	\$7.5 million			
Total	\$107 million			



#### More friendly-users medicines

#### With UNITAID funding, new treatments are put on the market where:

- Dosages are adapted to patients need pediatric, second line
- Medicines can be taken in the form of tablets (*fixed dose combinations*)
- Products are heat stable: no refrigeration needed anymore
- No need for water to dilute medicines (problem of access to drinkable water in some countries).
- More quality products are available: 16 new prequalified medicines in 2008



#### Better products at lower price

#### **Pediatric ARVs**



O Tables / 60 Carples United Stored Biologies Stored Bio

Before: Single dose syrups 16 bottles of syrup monthly US\$ 200 per patient per year Now (partnering with CHAI): Fixed dose combination 3 tablets a day US\$ 60 per patient per year



## Better products at lower price

## Tuberculosis

- A rotating stockpile that treats 5800 patients a year
- New faster diagnostics that can detect MDR-TB in just two days (previous test took six weeks)



## Better products at lower price

Malaria

- Investing in prevention with long lasting insecticide treated bed nets
- Provision of ACTs at lower costs
- UNITAID's recent commitment to the AMFm



UNITAID



164 for treatment of HIV/AIDS and related diseases

18 for treatment of tuberculosis (10 prequalified in 2007-08)

14 for treatment of malaria (9 prequalified in 2007-08)

Further products under evaluation in January 2009:


68 products for treatment of HIV/AIDS and related diseases

41 products for treatment of tuberculosis

17 products for treatment of malaria

#### **UNITAID's current and future challenges**





- \* Pending technical working group recommendation in January 2009
- \*\* Given Rifampicin's negative interactions with some ARV regimens
- \*\*\* Possible commodities to explore could include female condoms



UNIS POUR SOIGNER JUNTOS PARA CURAR TOGETHER TO HEAL

UNITAD

#### - une autre iClée de la mondialisation

uma **Outra** forma de globalização

another kind of globalization